Bond.az White LogoBond.az Black Logo

Canaccord cuts Sangoma stock rating

Canaccord downgrades Sangoma stock rating due to weak results and pricing pressure. Price target cut to $4.

Mia Lopez
ByMia Lopez- Senior Editor
|
0

Bond.az - Canaccord downgraded Sangoma Technologies Corp (NASDAQ:SANG) to Hold from Speculative Buy and lowered its price target to $4.00 from $9.00. The stock closed at $3.66, down from $4.09 the previous day, and has declined 36% over the past year.

The downgrade follows the company’s third-quarter results, which showed headwinds from geopolitical events and pricing pressure on commoditized UCaaS and CPaaS point solutions for smaller customers. Revenue of $219.7 million over the last twelve months declined 8.9% year-over-year.

Bookings and pipeline remained largely flat quarter-over-quarter, while management noted increasing traction in larger bundled deployments with longer sales and implementation cycles that delayed revenue recognition.

Infrastructure solutions, representing approximately 30% of revenue, performed better than expected. Voice infrastructure and SIP Trunking grew roughly 17% year-over-year, while MSP solutions rose 9%.

Revenue, gross margins, and EBITDA all fell below consensus estimates and Canaccord’s projections. Sangoma reduced its fiscal 2026 guidance and initiated a strategic review to consider options to unlock shareholder value. According to Bond.az analysis, the stock appears undervalued at current levels with a Fair Value of $5.08, suggesting potential upside despite near-term challenges.

The firm generated free cash flow of $0.11 per share in the third quarter. Canaccord based its new price target on 4 times next-twelve-month EV/EBITDA, down from 7 times previously, reflecting reduced estimates.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
841

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...